Ewa Błaszczyk
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ewa Błaszczyk has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Aneta Gawlik
Department of Pediatrics and Pediatric Endocrinology, Faculty of Medical Sciences, Medical University of Silesia, Katowice, Poland
3 shared publications Aneta Gawlik
Department of Pediatrics and Pediatric Endocrinology, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland
2 shared publicationsAnna-Mariia Shulhai
I. HORBACHEVSKY TERNOPIL NATIONAL MEDICAL UNIVERSITY, TERNOPIL, UKRAINE
2 shared publicationsJoanna Gieburowska
Department of Pediatrics and Pediatric Endocrinology, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland
2 shared publicationsAgnieszka Bielska-Brodziak
Faculty of Law and Administration, University of Silesia, Katowice, Poland
1 shared publicationAgnieszka Wiernik
Department of Pediatric Surgery and Urology, Medical University of Silesia, Katowice, Poland
1 shared publication
Latest Publications
- Open Access
- 27 June 2026
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 21
Refining the diagnosis of 46,XY disorders of sex development: insight from whole-exome sequencing
Introduction: Differences in sex development (DSD) with 46,XY karyotype are a group of rare congenital conditions affecting the structure and function of the urogenital system. Published data indicate, that despite the increasingly widespread use of genetic testing, the etiology remains unclear in approximately half of cases. Aim of the study: To clarify the molecular causes of 46,XY DSD by performing whole-exome sequencing (WES) in a precisely phenotyped and clinically comprehensively evaluated group of patients. Patients and methods: WES was performed in a consecutive cohort of 39 children diagnosed in our center as 46,XY DSD (aged 0.2–17.9 years). 32 were assigned male, 6 female, and 1 was a transgender boy. All patients underwent detailed clinical, hormonal and biochemical evaluation prior to genetic testing. Results: A genetic cause explaining DSD phenotype was identified in 8 children. Pathogenic variants were detected in 3 patients, including variants in the AR and DHX37 genes. Likely pathogenic variants were found in 5 patients, affecting the AR and HSD17B3 genes. Variants of uncertain significance (VUSs) were identified in 7 patients, involving genes with well-established relevance to DSD- NR5A1, DHX37, AR, MAMLD1, SOS2 and FAM111A . Although classified as VUSs these variants represent plausible contributors to the patients’ phenotypes. In the remaining children, no variants currently known or suspected to be associated with 46,XY DSD were identified. The most common confirmed etiology in the cohort was androgen insensitivity syndrome (AIS). In addition, pathogenic variants in genes not linked to DSD were identified in 7 patients, demonstrating the broader clinical utility of WES. Conclusions: Our findings confirm that even a broad, high-throughput method such as WES fails to establish the molecular cause of 46,XY DSD in a substantial proportion of well-phenotyped patients, while at the same time enabling the identification of pathogenic variants in genes unrelated to DSD. We observed frequent genotype–phenotype discordance: similar clinical phenotypes could be associated with different genotypes, whereas the same gene variant could present with variable clinical expression. Re-analysis of WES data after 12–24 months should be considered in patients without a definitive diagnosis or in those who develop additional clinical features.
- 27 June 2026
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 21
Open AccessRefining the diagnosis of 46,XY disorders of sex development: insight from whole-exome sequencing
Introduction: Differences in sex development (DSD) with 46,XY karyotype are a group of rare congenital conditions affecting the structure and function of the urogenital system. Published data indicate, that despite the increasingly widespread use of genetic testing, the etiology remains unclear in approximately half of cases. Aim of the study: To clarify the molecular causes of 46,XY DSD by performing whole-exome sequencing (WES) in a precisely phenotyped and clinically comprehensively evaluated group of patients. Patients and methods: WES was performed in a consecutive cohort of 39 children diagnosed in our center as 46,XY DSD (aged 0.2–17.9 years). 32 were assigned male, 6 female, and 1 was a transgender boy. All patients underwent detailed clinical, hormonal and biochemical evaluation prior to genetic testing. Results: A genetic cause explaining DSD phenotype was identified in 8 children. Pathogenic variants were detected in 3 patients, including variants in the AR and DHX37 genes. Likely pathogenic variants were found in 5 patients, affecting the AR and HSD17B3 genes. Variants of uncertain significance (VUSs) were identified in 7 patients, involving genes with well-established relevance to DSD- NR5A1, DHX37, AR, MAMLD1, SOS2 and FAM111A . Although classified as VUSs these variants represent plausible contributors to the patients’ phenotypes. In the remaining children, no variants currently known or suspected to be associated with 46,XY DSD were identified. The most common confirmed etiology in the cohort was androgen insensitivity syndrome (AIS). In addition, pathogenic variants in genes not linked to DSD were identified in 7 patients, demonstrating the broader clinical utility of WES. Conclusions: Our findings confirm that even a broad, high-throughput method such as WES fails to establish the molecular cause of 46,XY DSD in a substantial proportion of well-phenotyped patients, while at the same time enabling the identification of pathogenic variants in genes unrelated to DSD. We observed frequent genotype–phenotype discordance: similar clinical phenotypes could be associated with different genotypes, whereas the same gene variant could present with variable clinical expression. Re-analysis of WES data after 12–24 months should be considered in patients without a definitive diagnosis or in those who develop additional clinical features.
- Open Access
- 1 January 2025
- Published by Termedia Sp. z.o.o. in Pediatric Endocrinology Diabetes and Metabolism
- Vol. 31 (4) , 161-168
Long-term effects of growth hormone on body composition and metabolic parameters in girls with Turner syndrome
Patients with Turner syndrome (TS) are at increased risk of metabolic complications, partly as a consequence of truncal obesity, which can already appear in childhood. Growth hormone (GH) therapy is widely used in this population and is known to exert a beneficial effect on body composition (BC). The study aims to evaluate the impact of GH therapy on BC and explore associations between BC parameters and components of metabolic syndrome in girls with TS during a 5-year follow-up. Twenty-one TS patients were enrolled. Auxological, BC, and biochemical parameters were assessed at baseline (V1), after 3 years (V3), and after 5 years (V5) of GH therapy. Results were available for 21, 20, and 13 patients, respectively. Biochemical phenotypes were determined using carbohydrate and lipid parameters. The only BC parameter that significantly increased during GH therapy was fat-free mass (FFM). Along with rising insulin-like growth factor 1 levels, fasting and postprandial insulin concentrations, as well as insulin resistance, increased during treatment. Total cholesterol decreased, although without significant changes in its fractions. No significant correlations were found between BC parameters, glucose, and total cholesterol during the GH 5-year follow-up. Growth hormone therapy exerts a beneficial effect on BC in girls with TS, reflected by an increase in FFM. However, carbohydrate metabolism should be closely monitored, in line with national program requirements, due to the increased insulin resistance during GH therapy. Lifestyle recommendations promoting healthy behaviors should be provided to all patients with TS.
- 1 January 2025
- Published by Termedia Sp. z.o.o. in Pediatric Endocrinology Diabetes and Metabolism
- Vol. 31 (4) , 161-168
Open AccessLong-term effects of growth hormone on body composition and metabolic parameters in girls with Turner syndrome
Patients with Turner syndrome (TS) are at increased risk of metabolic complications, partly as a consequence of truncal obesity, which can already appear in childhood. Growth hormone (GH) therapy is widely used in this population and is known to exert a beneficial effect on body composition (BC). The study aims to evaluate the impact of GH therapy on BC and explore associations between BC parameters and components of metabolic syndrome in girls with TS during a 5-year follow-up. Twenty-one TS patients were enrolled. Auxological, BC, and biochemical parameters were assessed at baseline (V1), after 3 years (V3), and after 5 years (V5) of GH therapy. Results were available for 21, 20, and 13 patients, respectively. Biochemical phenotypes were determined using carbohydrate and lipid parameters. The only BC parameter that significantly increased during GH therapy was fat-free mass (FFM). Along with rising insulin-like growth factor 1 levels, fasting and postprandial insulin concentrations, as well as insulin resistance, increased during treatment. Total cholesterol decreased, although without significant changes in its fractions. No significant correlations were found between BC parameters, glucose, and total cholesterol during the GH 5-year follow-up. Growth hormone therapy exerts a beneficial effect on BC in girls with TS, reflected by an increase in FFM. However, carbohydrate metabolism should be closely monitored, in line with national program requirements, due to the increased insulin resistance during GH therapy. Lifestyle recommendations promoting healthy behaviors should be provided to all patients with TS.
- Open Access
- 11 July 2023
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 14, 1216464
Components of the metabolic syndrome in girls with Turner syndrome treated with growth hormone in a long term prospective study
Background: Components of the metabolic syndrome are more common in patients with Turner syndrome (TS) than in the general population. Long-term growth hormone (GH) treatment also affects the parameters of carbohydrate metabolism. Therefore, all these factors should be monitored in girls with TS.Objective: To assess the occurrence of metabolic syndrome components in TS girls before GH treatment and to monitor changes in metabolic parameters throughout GH therapy.Patients and method: 89 TS patients were enrolled in the study. Clinical and laboratory data after the 1st (V1), 3rd (V3), 5th (V5) and 10th (V10) year of GH therapy was available respectively in 60, 76, 50 and 22 patients. The patients’ biochemical phenotypes were determined by glucose 0’, 120’, insulin 0’, 120’, HOMA-IR, Ins/Glu ratio, HDL-cholesterol and triglycerides (TG) concentration.Results: Obesity was found during V0 in 7.9% of patients,V1 - 5%, V3 - 3.9%, V5 - 2%, V10 – 0%. No patient met diagnostic criteria for diabetes. A significant increase in the basal plasma glucose 0’ was found in the first five years of therapy (pV0-V1 < 0.001; pV0-V3 = 0.006; pV0-V5 < 0.001). V10 glucose 120’ values were significantly lower than at the onset of GH treatment (pV0-V10 = 0.046). The serum insulin 0’ and 120’ concentrations as well as insulin resistance increased during treatment. No statistically significant differences in serum TG and HDL-cholesterol levels during GH therapy were found.Conclusion: The development of insulin resistance and carbohydrate metabolism impairment have the greatest manifestations during GH therapy in girls with TS. Monitoring the basic parameters of carbohydrate-lipid metabolism in girls with TS seems particularly important.
- 11 July 2023
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 14, 1216464
Open AccessComponents of the metabolic syndrome in girls with Turner syndrome treated with growth hormone in a long term prospective study
Background: Components of the metabolic syndrome are more common in patients with Turner syndrome (TS) than in the general population. Long-term growth hormone (GH) treatment also affects the parameters of carbohydrate metabolism. Therefore, all these factors should be monitored in girls with TS.Objective: To assess the occurrence of metabolic syndrome components in TS girls before GH treatment and to monitor changes in metabolic parameters throughout GH therapy.Patients and method: 89 TS patients were enrolled in the study. Clinical and laboratory data after the 1st (V1), 3rd (V3), 5th (V5) and 10th (V10) year of GH therapy was available respectively in 60, 76, 50 and 22 patients. The patients’ biochemical phenotypes were determined by glucose 0’, 120’, insulin 0’, 120’, HOMA-IR, Ins/Glu ratio, HDL-cholesterol and triglycerides (TG) concentration.Results: Obesity was found during V0 in 7.9% of patients,V1 - 5%, V3 - 3.9%, V5 - 2%, V10 – 0%. No patient met diagnostic criteria for diabetes. A significant increase in the basal plasma glucose 0’ was found in the first five years of therapy (pV0-V1 < 0.001; pV0-V3 = 0.006; pV0-V5 < 0.001). V10 glucose 120’ values were significantly lower than at the onset of GH treatment (pV0-V10 = 0.046). The serum insulin 0’ and 120’ concentrations as well as insulin resistance increased during treatment. No statistically significant differences in serum TG and HDL-cholesterol levels during GH therapy were found.Conclusion: The development of insulin resistance and carbohydrate metabolism impairment have the greatest manifestations during GH therapy in girls with TS. Monitoring the basic parameters of carbohydrate-lipid metabolism in girls with TS seems particularly important.
- 12 January 2022
- Published by VM Media Group sp. z o.o in Ginekologia Polska
- Vol. 93 (2) , 168-172
Safety and efficiency of COVID-19 vaccination during pregnancy and breastfeeding
Despite the development of effective and safe vaccines, the contributions of pregnant women in clinical trials of vaccines have been excluded. Similarly, vaccine trials did not include breastfeeding women. This article is an overview of studies on immunization during pregnancy and breast-feeding. The manuscript is intended to collect the current data on the effectiveness and safety of COVID-19 vaccines in order to facilitate medical decision. Despite the development of effective and safe vaccines, the contributions of pregnant women in clinical trials of vaccines have been excluded. Similarly, vaccine trials did not include breastfeeding women. This article is an overview of studies on immunization during pregnancy and breast-feeding. The manuscript is intended to collect the current data on the effectiveness and safety of COVID-19 vaccines in order to facilitate medical decision.
- 12 January 2022
- Published by VM Media Group sp. z o.o in Ginekologia Polska
- Vol. 93 (2) , 168-172
Safety and efficiency of COVID-19 vaccination during pregnancy and breastfeeding
Despite the development of effective and safe vaccines, the contributions of pregnant women in clinical trials of vaccines have been excluded. Similarly, vaccine trials did not include breastfeeding women. This article is an overview of studies on immunization during pregnancy and breast-feeding. The manuscript is intended to collect the current data on the effectiveness and safety of COVID-19 vaccines in order to facilitate medical decision. Despite the development of effective and safe vaccines, the contributions of pregnant women in clinical trials of vaccines have been excluded. Similarly, vaccine trials did not include breastfeeding women. This article is an overview of studies on immunization during pregnancy and breast-feeding. The manuscript is intended to collect the current data on the effectiveness and safety of COVID-19 vaccines in order to facilitate medical decision.
- Open Access
- 29 August 2018
- Published by Wiley in International Journal of Endocrinology
- Vol. 2018, 1-6
Selected Metabolic Markers in Girls with Turner Syndrome: A Pilot Study
Background. Turner syndrome (TS) predisposes an individual to obesity and related metabolic disorders. As the TS population is at a higher risk of cardiovascular diseases and malformations, research into laboratory markers of metabolic complications has been ongoing. Special significance has recently been attributed to matrix metalloproteinases (MMPs), their inhibitors (TIMPs), and neurotrophic factors, such as BDNF and GDNF.Objective. To establish whether cardiometabolic risk in patients with TS is reflected in the concentrations of metalloproteinases and neurotrophic factors.Method. The concentrations of circulating MMP-1, MMP-2, MMP-9, TIMP-1, BDNF, GDNF, and VEGF were measured in 17 patients with TS. The control group was composed of 11 girls with nonpathologic short stature and normal karyotype.Results. There were no differences in chronological or bone age. No significant differences were observed in mean weight, although the-score BMI was higher in the study group. The mean baseline values of MMP-1 and BDNF were significantly lower in the control group than in the study group (,). Regression analysis revealed a positive correlation between MMP-1 concentrations andZ-score BMI (,) and between BDNF and-score BMI (,).Conclusion. Our pilot study showed that MMP-1 may be a potential indicator of a higher risk of cardiometabolic complications in girls with TS. The elevated concentrations of BDNF in normal-weight girls with TS need to be studied further, taking into consideration the influence of estrogen-androgen imbalance.- 29 August 2018
- Published by Wiley in International Journal of Endocrinology
- Vol. 2018, 1-6
Open AccessSelected Metabolic Markers in Girls with Turner Syndrome: A Pilot Study
Background. Turner syndrome (TS) predisposes an individual to obesity and related metabolic disorders. As the TS population is at a higher risk of cardiovascular diseases and malformations, research into laboratory markers of metabolic complications has been ongoing. Special significance has recently been attributed to matrix metalloproteinases (MMPs), their inhibitors (TIMPs), and neurotrophic factors, such as BDNF and GDNF.Objective. To establish whether cardiometabolic risk in patients with TS is reflected in the concentrations of metalloproteinases and neurotrophic factors.Method. The concentrations of circulating MMP-1, MMP-2, MMP-9, TIMP-1, BDNF, GDNF, and VEGF were measured in 17 patients with TS. The control group was composed of 11 girls with nonpathologic short stature and normal karyotype.Results. There were no differences in chronological or bone age. No significant differences were observed in mean weight, although the-score BMI was higher in the study group. The mean baseline values of MMP-1 and BDNF were significantly lower in the control group than in the study group (,). Regression analysis revealed a positive correlation between MMP-1 concentrations andZ-score BMI (,) and between BDNF and-score BMI (,).Conclusion. Our pilot study showed that MMP-1 may be a potential indicator of a higher risk of cardiometabolic complications in girls with TS. The elevated concentrations of BDNF in normal-weight girls with TS need to be studied further, taking into consideration the influence of estrogen-androgen imbalance. - Open Access
- 4 June 2018
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 9, 307
Immunological Profile and Predisposition to Autoimmunity in Girls With Turner Syndrome
Objective: The risk of autoimmune diseases (AD) in patients with Turner Syndrome (TS) is twice higher than in the general female population and four times higher than in the male population. The causes of the increased incidence of AD in TS are still under discussion. We hypothesized the presence of a specific humoral, cellular, and regulatory T cell (Treg) immunity profile which predisposes to AD, disorders of immunity, and disorders of immune regulation. Methods: The study encompassed 37 girls with TS and with no signs of infection. The control group included 11 healthy girls with no hormonal disorders. A medical history focused on AD and immunity disorders was taken from all participants. The levels of: immunoglobulins IgG, IgA, IgM, total lymphocytes, lymphocytes subpopulations CD3+, CD4+, CD8+, CD19+, natural killer cells, Treg cells (CD4+ CD25+ CD127− FOXP3+), anti-inflammatory cytokines (interleukin-10, transforming growth factor-β), anti-nuclear antibodies, glutamic acid decarboxylase (GAD65 Abs), anti-thyroid peroxidase (anti-TPO Ab), and anti-thyroglobulin (anti-TG Ab) autoantibodies were determined in each participant. Results: The mean age and BMI in the TS group and in controls were comparable (11.9 ± 4.1 vs. 12.5 ± 4.0 years; 19.2 ± 3.4 vs. 19.7 ± 4.6, p > 0.05). Mean hSDS was significantly higher in controls (−2.2 ± 0.9 vs. −0.4 ± 1.5, p < 0.0001). AD and recurrent otitis media with complications were previously confirmed in 9 (24.3%) and 10 (27.0%) girls with TS. The TS group had significantly lower levels of IgG (p = 0.02), lower%CD4 (p < 0.001) and a significantly lower CD4:CD8 ratio than the controls (p < 0.001). There were no differences in mean Treg% between girls with TS and healthy controls. However, comparing Treg% between the TS group with coexisting autoimmunity and the remaining participants, a statistically significant difference was observed (2.09 ± 0.5 vs. 2.77 ± 1.6, p = 0.048). Patients with iXq had lower CD4% and more frequently had positive anti-TPO Ab and anti-TG Ab compared to the remaining girls with TS and controls (p = 0.001, p < 0.001, p = 0.01). Conclusion: TS predisposes to AD, especially if associated with coexisting iXq. Our preliminary findings show that patients with TS may present a specific profile of humoral and cellular immunity markers, different from healthy girls.
- 4 June 2018
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 9, 307
Open AccessImmunological Profile and Predisposition to Autoimmunity in Girls With Turner Syndrome
Objective: The risk of autoimmune diseases (AD) in patients with Turner Syndrome (TS) is twice higher than in the general female population and four times higher than in the male population. The causes of the increased incidence of AD in TS are still under discussion. We hypothesized the presence of a specific humoral, cellular, and regulatory T cell (Treg) immunity profile which predisposes to AD, disorders of immunity, and disorders of immune regulation. Methods: The study encompassed 37 girls with TS and with no signs of infection. The control group included 11 healthy girls with no hormonal disorders. A medical history focused on AD and immunity disorders was taken from all participants. The levels of: immunoglobulins IgG, IgA, IgM, total lymphocytes, lymphocytes subpopulations CD3+, CD4+, CD8+, CD19+, natural killer cells, Treg cells (CD4+ CD25+ CD127− FOXP3+), anti-inflammatory cytokines (interleukin-10, transforming growth factor-β), anti-nuclear antibodies, glutamic acid decarboxylase (GAD65 Abs), anti-thyroid peroxidase (anti-TPO Ab), and anti-thyroglobulin (anti-TG Ab) autoantibodies were determined in each participant. Results: The mean age and BMI in the TS group and in controls were comparable (11.9 ± 4.1 vs. 12.5 ± 4.0 years; 19.2 ± 3.4 vs. 19.7 ± 4.6, p > 0.05). Mean hSDS was significantly higher in controls (−2.2 ± 0.9 vs. −0.4 ± 1.5, p < 0.0001). AD and recurrent otitis media with complications were previously confirmed in 9 (24.3%) and 10 (27.0%) girls with TS. The TS group had significantly lower levels of IgG (p = 0.02), lower%CD4 (p < 0.001) and a significantly lower CD4:CD8 ratio than the controls (p < 0.001). There were no differences in mean Treg% between girls with TS and healthy controls. However, comparing Treg% between the TS group with coexisting autoimmunity and the remaining participants, a statistically significant difference was observed (2.09 ± 0.5 vs. 2.77 ± 1.6, p = 0.048). Patients with iXq had lower CD4% and more frequently had positive anti-TPO Ab and anti-TG Ab compared to the remaining girls with TS and controls (p = 0.001, p < 0.001, p = 0.01). Conclusion: TS predisposes to AD, especially if associated with coexisting iXq. Our preliminary findings show that patients with TS may present a specific profile of humoral and cellular immunity markers, different from healthy girls.
- 1 January 2016
- Published by Termedia Sp. z.o.o. in Pediatric Endocrinology Diabetes and Metabolism
- Vol. 22 (3) , 125-131
Neurotrophins, VEGF and matrix metalloproteinases: new markers or causative factors of metabolic syndrome components?
Currently the number of obese people in the world is still growing, as well as people suffering from other metabolic disorders included in the metabolic syndrome. The factors responsible for this are anincorrect diet, low physical activity, as well as a tendency of the population to aging. Therefore, more research aimed at seeking potential factors that could in the future be useful in the prevention or treatment of obesity and related diseases is carried out. In this article we present a few selected biochemical markers, affecting the metabolism of carbohydrates and lipids in a way that is not always clear and obvious.
- 1 January 2016
- Published by Termedia Sp. z.o.o. in Pediatric Endocrinology Diabetes and Metabolism
- Vol. 22 (3) , 125-131
Neurotrophins, VEGF and matrix metalloproteinases: new markers or causative factors of metabolic syndrome components?
Currently the number of obese people in the world is still growing, as well as people suffering from other metabolic disorders included in the metabolic syndrome. The factors responsible for this are anincorrect diet, low physical activity, as well as a tendency of the population to aging. Therefore, more research aimed at seeking potential factors that could in the future be useful in the prevention or treatment of obesity and related diseases is carried out. In this article we present a few selected biochemical markers, affecting the metabolism of carbohydrates and lipids in a way that is not always clear and obvious.